logo-loader
Micro Focus International plc

Micro Focus boosted by Goldman Sachs upgrade to ‘buy’ from ‘neutral’ following recent trading update

The US investment bank's analysts said: “An in-line FY18 trading update suggests that revenue declines are moderating and sell-side estimates have likely bottomed”

Micro Focus office
Goldman Sachs also raised its 12-month target price for Micros Focus to 1,700p, up from 1,300p previously

Goldman Sachs gave a lift to blue-chip software firm Micro Focus International PLC (LON:MCRO) on Wednesday, upgrading its rating to ‘buy’ from ‘neutral’ following the group’s recent trading update.

The US investment bank also raised its 12-month target price to 1,700p, up from 1,300p previously, with Micro Focus shares trading at 1,427.50p in mid-afternoon trading, up 9.2% on Tuesday’s closing price.

READ: Micro Focus raises revenue guidance for year just ended

In a note to clients, Goldman’s analysts said: “Following a period of significant M&A execution issues which led to turbulent sales growth in FY18, we believe that the dust is starting to settle at Micro Focus.”

They added: “An in-line FY18 trading update suggests that revenue declines are moderating and sell-side estimates have likely bottomed.”

The analysts concluded: “In our view, cost synergies from the integration of HPE Software, and ongoing and future capital returns, should come to  the fore with the stock trading at a near term trough multiple of 7.5x 2019E PF EPS and revenue declines not deteriorating further.”

Quick facts: Micro Focus International plc

Price: £11.62

Market: LSE
Market Cap: £38.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

41 minutes ago

RNS

Transaction in Own Shares

11 hours, 31 minutes ago

Transaction in Own Shares

1 day, 11 hours ago

Transaction in Own Shares

4 days, 11 hours ago

Transaction in Own Shares

5 days, 11 hours ago

Transaction in Own Shares

6 days, 11 hours ago

Transaction in Own Shares

1 week, 1 day ago

2 min read